Introduction
============

Metabolic disorders, such as obesity, dyslipidemia, and hyperglycemia, are closely related to AT dysfunction, and indeed AT is considered one of the most promising therapeutic targets ([@B30]; [@B43]). AT is a metabolic and endocrine organ consisting mainly of adipocytes. In addition, AT contains other cell types collectively named SVF, which includes MSCs, preadipocytes, endothelial cells, fibroblasts, and a variety of immune cells such as macrophages and T regulatory cells. Mammals have two main types of AT: WAT comprises mainly of WA, which store excess energy as triglycerides; and BAT, characterized by mitochondria-rich adipocytes, which express UCP1 that enables dissipation of energy by production of heat. Within WAT, there are also UCP1-positive cells with thermogenic capacity called beige or brite (brown-in-white) adipocytes. Cold exposure or other specific factors can produce browning of WAT ([@B32]; [@B42]). WAT and BAT are innervated by the sympathetic nervous system that together with hormones and other factors regulates adipocyte function ([@B8]). Adipocytes are also regulated by nucleosides and nucleotides, such as adenosine and ATP.

Generally, ATP is released from sympathetic nerves ([@B9]) and this is also likely in AT ([@B29]), though only sympathetic nerves innervating BAT were found to express the ATP transporter VNUT ([@B63]). Many other non-excitable cells, such as epithelial, glial, stromal, and immune cells release ATP in basal conditions ([@B16]) and in response to various patho-/physiological stimuli ([@B40]; [@B57]; [@B46]). Similarly, ATP could be released from adipocytes ([@B29]; [@B1]). The mechanism of ATP release is not extensively studied; so far one study suggests channel pannexin-1 ([@B1]) and another vesicular-based mechanism ([@B63]). Other cells in AT could also release ATP, contributing to a purinergic cross-talk between different cells, but such signaling is yet to be explored. In the extracellular space ATP is hydrolyzed to adenosine by one or more ecto-nucleotidases belonging to four families: ecto-nucleoside triphosphate diphosphorylases (CD39 type), ecto-5′-nucleotidase (CD73 type), ecto-nucleotide pyrophosphatase/phosphodiesterases (NPP) and alkaline phosphatases (APs) ([@B85]). Interestingly, one of the enzymes NPP2, also known as phospholipase D or autotaxin, is multifunctional and released by adipocytes, and up-regulated autotaxin expression correlates with obesity ([@B62]). Nevertheless, it is most often assumed that adipocytes can release adenosine, possibly through nucleoside transporters ([@B3]; [@B29]).

Adenosine, ATP, and other nucleotides signal through purinergic receptors that operate in virtually all mammalian cells, and it can be disturbed in various diseases, including metabolic syndrome, and therefore is attractive for therapeutic targeting ([@B10]; [@B11]; [@B13]; [@B36]). Here, we summarize the current knowledge about (i) the expression and function of adenosine receptors (P1R) and P2 receptors (P2XR and P2YR) in white, brown, and possibly in beige adipocytes; (ii) their role in the onset and progression of metabolic disorders; and (iii) their potential as therapeutic targets. In some cases, it is difficult to dissect the contribution of purinergic signaling in adipocytes from the AT/whole body effects ([@B60]). This is because the SVF in AT and other organs express purinergic receptors, and various conditions (e.g., inflammation) and experimental set up (e.g., whole-body receptor KOs or systemic receptor modulators) will complicate interpretation of effects.

Adenosine Receptors in Adipose Tissue
=====================================

Adenosine accumulates extracellularly in response to metabolic stress, tissue injury, hypoxia and inflammation and concentrations can range from nanomolar to micromolar in physiological and pathophysiological conditions, respectively ([@B25]). Adenosine can bind to four different G-protein-coupled receptors A~1~, A~2A~, A~2B~, and A~3~. A~1~R and A~2A~R have high affinity for adenosine, while A~2B~R and A~3~R have relatively lower affinity. A~1~R and A~3~R are coupled to G~i/o~ proteins and their activation inhibits cAMP production and decreases PKA activity. A~2A~R and A~2B~R are coupled to G~s/olf~ proteins and stimulate cAMP production, thus activating PKA. In addition, some adenosine receptors also activate PLC, Ca^2+^ signaling and mitogen-activated protein kinases ([@B26]).

Adenosine has a key role in regulating many patho-/physiological processes in AT and adipocytes (**Figure [1](#F1){ref-type="fig"}**). The most studied adenosine receptor is the A~1,~ identified in WAT of many species ([@B76]; [@B45]; [@B72]; [@B55]; [@B75]). Using pharmacological tools and whole body A~1~R KO mice, it was shown that activation of this receptor in rodents has anti-lipolytic effects mediated by inhibition of cAMP production and decrease in PKA and lipase activities ([@B24]; [@B69]; [@B20]; [@B37]). Rat WA are more responsive than BA to inhibition of lipolysis by the A~1~R stimulators PIA and NECA ([@B66]), probably due to higher expression of the receptor in WA ([@B29]). A~1~R activation also increases lipogenesis in mouse and rat WA ([@B37]; [@B74]). The A~1~R is also implicated in adipogenesis ([@B28]) and leptin production in WA ([@B14]; [@B64]). All these A~1~R-mediated effects highlight the importance of adenosine signaling in AT, and predict impact on whole body metabolism. In accordance, A~1~R KO mice have increased fat mass and body weight, and impaired glucose tolerance and insulin sensitivity ([@B23]; [@B81]). In contrast, mice overexpressing the A~1~R in AT are protected from obesity-induced insulin resistance ([@B22]).
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Another fairly well studied receptor is the A~2B~R, detected in adipocytes and SVF ([@B29]). *In vitro* experiments on murine pre-osteoblast cell line expressing either human A~2B~R or A~1~R showed that A~1~R stimulated adipogenesis, while the A~2B~R inhibited both adipogenesis and lipogenesis, supporting osteoblastogenesis pathways ([@B28]). In *in vivo* experiments, A~2B~R expression seems to correlate with parameters of obesity, both in rodents and humans, and the receptor is upregulated in visceral AT of mice fed HFD ([@B39]). Genetic KO of the receptor is also associated with metabolic disorders. Whole body A~2B~R KO led to AT inflammation, insulin resistance, impaired glucose and lipid metabolism in mice ([@B39]; [@B17]; [@B61]). Importantly, systemic administration of the A~2B~ specific agonist BAY 60-6583, following HFD regime, lowered plasma glucose, insulin and IL-6 levels, and ameliorated type-2 diabetes in mice ([@B39]). These animal studies and a recent study ([@B38]) are interpreted mainly in terms of the A~2B~R activation of WAT macrophage. Nevertheless, involvement of adipocyte A~2B~R cannot be excluded.

The A~2A~R may have a major role in BAT, where it is more abundantly expressed compared to WAT ([@B29]). Early studies showed that adenosine inhibited lipolysis in BA from rat or hamster, probably via A~1~R ([@B67]; [@B79]). In contrast, recent work shows that adenosine and A~2A~R agonists (CGS21680 or PSB-0777) activated lipolysis in human and murine BA, and to explain differences in the studies authors proposed species-related differential receptor expression ([@B29]). Moreover, agonists used in this study increased energy expenditure, induced browning of WAT, improved glucose tolerance and protected C57Bl/6 mice from diet-induced obesity, thus revealing a promising thermogenic effect of adenosine. Similar effect on glucose homeostasis was reported for another A~2A~R agonist CGS21680 administered to Swiss strain mice fed with HFD ([@B18]). No alteration in body weight or adiposity was detected, though decrease in some inflammatory markers was observed. The difference in animal obesity detected in the two studies could be due to different time regimes of drug treatment (8 weeks vs. 2 weeks), differences in strains of mice used (see below for comments on C57Bl/6 strain), or specificity of different A~2A~R agonists used.

There are only a few studies on A~3~R in adipocytes/AT. Isolated human WA express higher levels of A~3~R mRNA compared to BA. But inhibition of the receptor with MRS1523 had no significant effect on modulating lipolysis, at least in murine BA ([@B29]). However, the A~3~R KO mice had less abdominal and total body fat, and mice were protected from hypertension and cardiovascular diseases in the chronic kidney disease model tested ([@B82]).

Taken together, there is strong evidence that adipocytes express all types of adenosine receptors that regulate patho-/physiological processes (**Figure [1](#F1){ref-type="fig"}**). There is a consensus that A~1~R regulates lipolysis and therefore FFAs levels, which play a significant role in the pathogenesis of insulin resistance, diabetes, and cardiovascular diseases ([@B19]; [@B2]). Several A~1~R agonists, e.g., SDZWAG994 ([@B35]), ARA ([@B84]), and RPR749 ([@B70]), have been clinically evaluated as anti-lipolytic agents for the treatment of hypertriglyceridemia and type-2 diabetes. Though, development of full A~1~R agonists has been limited by (i) the debilitating side effects induced by the activation of the receptors in heart and kidney of animal models ([@B6]; [@B80]); and (ii) a well-characterized desensitization of the receptor after repeated exposure to full agonists ([@B33]; [@B21]). However, selective partial A~1~R agonists, e.g., CPA and GS-9667 (CVT-3619), effectively lowered plasma FFA levels without detectable cardiovascular side effects in rodents and humans ([@B20],[@B21]). These effects were achieved by administering lower concentrations of these drugs, which acted predominantly on AT, as it has larger A~1~R reserve compared to other tissues (i.e., atrioventricular node) ([@B71]). Furthermore, given the role of the A~2B~R in glucose and lipid homeostasis, and AT inflammation, this receptor could be a promising target for the treatment of metabolic diseases. Finally, finding that activation of A~2A~R induces beiging of WA and activates BA ([@B29]) may stimulate development of new pharmacological interventions for the treatment of obesity and metabolic disease.

Purinergic P2 Receptors in Adipose Tissue
=========================================

In contrast to adenosine, patho-/physiological functions of ATP and other nucleotides have not been studied so extensively in AT. Tri- and di-nucleotides signal through P2R belonging to two main families: the ionotropic P2XRs and the metabotropic G-protein coupled P2YRs. The P2XRs (P2X1--7) are ligand-gated cation channels activated primarily by ATP ([@B56]). The P2YR subtypes can be stimulated by different endogenous nucleotides and most potent ones (in humans) are given in brackets. P2Y1R (ADP), P2Y2R (UTP), P2Y4R (UTP), P2Y6R (UDP) receptors couple to G~q~ proteins and thus activate PLC-β, mobilizing Ca^2+^ from intracellular stores. P2Y11R (ATP) couple in addition to G~s~ proteins increase cAMP, while P2Y12R (ADP), P2Y13R (ADP), and P2Y14R (UDP, UDP-glucose) couple to G~i~ proteins and inhibit cAMP formation ([@B78]).

Early studies by [@B49],[@B50]) and [@B48] used patch-clamp, Ca^2+^ imaging and mRNA analysis to fingerprint functional P2XRs and P2YRs in WA and BA. Here, we will focus on role of P2Rs in regulating multiple adipocyte-specific processes as summarized in **Figure [2](#F2){ref-type="fig"}**.
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P2Rs regulate adipogenesis. Several studies used expression profiling and functional assays to describe that P2Y1R, P2Y2R or P2Y4R and P2Y11R positively affected adipogenic differentiation of stem cells derived from bone marrow or AT ([@B41]; [@B86]; [@B15]; [@B53]). In contrast, P2Y4R activation (UTP, MRS4062) inhibited cardiac AT-derived stem cells differentiation and P2Y4R KO mice developed bigger cardiac AT mass and higher expression of UCP1 ([@B51]). The opposite effect of P2Y4R in the mentioned studies could be related to the higher receptor expression in cardiac AT compared to other fat depots and/or beige/BA lineage in the cardiac tissue. Three other receptors have anti-adipogenic effects -- P2Y13, P2Y14, and P2X7 ([@B86]; [@B7]). Interestingly, P2X7R KO male mice had increased body weight, adipocyte hyperplasia in fat pads, and ectopic lipid accumulation in kidney, salivary glands, and pancreas ([@B5]). Other *in vitro* and *in vivo* studies indicate that the P2X7R stimulation directs differentiation of MSCs toward the osteoblast lineage rather than toward adipocytes ([@B52]).

P2Rs are also implicated in lipid metabolism. One study on isolated rat WA shows that ATP, UTP, and BzATP, probably by activating different P2Rs, had dual effects -- activated lipolysis and inhibited insulin-induced leptin production ([@B47]). In contrast, no lipolytic effect of ATP was found in a similar cellular model ([@B68]). The explanation for these divergent results could be that the two studies used different ATP concentrations, thus affecting different palette of P2Rs. Furthermore, in the latter study on isolated WA, ATP stimulated lipogenesis but had no effect on glucose transport ([@B68]).

The role of purinergic signaling in glucose uptake in adipocytes has been investigated in 1980s. Two studies showed that low concentrations of ATP inhibited insulin-stimulated glucose transport in rat fat cells ([@B12]; [@B31]), and it was assumed that extracellular ATP had direct inhibitory effect on the insulin receptor. More recently, it was shown that P2Y6R activation by UDP or MRS2957 increased GLUT-4 translocation and glucose uptake in primary WA and 3T3-L1 cells ([@B4]).

In addition to effects on adipogenesis, lipid metabolism, and glucose transport, P2Rs affect leptin and adiponectin production and secretion, but activation of different P2R subtypes might lead to opposite effects. ATP and BzATP reduced leptin mRNA levels and inhibited insulin-induced leptin secretion in rat WA ([@B47]). In another study, inhibition of P2Y1R by MRS2500 decreased leptin production under basal and insulin-stimulated conditions in isolated mouse WA ([@B44]). Furthermore, the study showed that plasma leptin was lower in mice lacking P2Y1R, however, in mice on HFD the plasma leptin was enhanced and the inhibitory effect of receptor KO was not observed. Stimulation of P2Y4R by UTP or MRS4062 inhibited adiponectin expression and secrection in cardiac adipocytes and P2Y4R KO mice showed increased adiponectin secrection in hypoxia and a cardioprotective phenotype ([@B51]).

Adenosine triphosphate is generally considered as an inflammatory molecule ([@B34]). Particularly the P2X7R mediates inflammation in AT. In primary adipocytes from rat epididymal fat, millimolar concentrations of ATP evoked inflammatory response and led to impaired insulin signaling and glucose uptake ([@B83]). Visceral and subcutaneous human AT express functional P2X7R, which could be involved in release of inflammatory cytokines such as IL-6, TNFα, and PAI-1 ([@B54]). Interestingly, this study showed that P2X7R expression appeared to be high in adipocytes isolated from subjects affected by metabolic syndrome. The P2X7R and NLRP3 inflammasome expression and IL-1β secretion was elevated in metabolically unhealthy obese individuals and the receptor expression correlated with body mass index and metabolic syndrome scores ([@B58]). Whether this was due to effects on adipocytes or infiltrating immune cells is not clear ([@B59]). In contrast, an earlier study concluded that the P2X7R was not involved in obesity-associated inflammasome activation. This was based on the observation that P2X7R KO mice on the C57BL/6 background and fed on HFD were not protected from obesity, AT inflammation and associated metabolic abnormalities ([@B73]). The C57BL/6 mice though have a single nucleotide polymorphism in the P2X7R that compromises the immune response ([@B65]), which could explain discrepancies in inflammasome activation in the two studies.

Rodent BA, express several P2X and P2Y receptors and stimulation with ATP leads to exocytosis and heat production ([@B49]; [@B48]). In a more recent study, ATPγS, enhanced UCP1 expression and induced browning in BAT in conditions of low adaptive thermogenesis and b-adrenergic receptor KO mice ([@B63]). This effect is most likely exerted via more than one receptor and P2X5R, P2X7R, and P2Y12R are overexpressed in β-less BAT. Interestingly, P2X5R is proposed as a novel cell surface marker for beige and BA as its mRNA levels are markedly higher in mouse BAT compared to WAT and other tissues ([@B77]). Furthermore, the P2X5R expression increased in both BAT and subcutaneous WAT upon chronic cold exposure, paralleling expression of UCP1 ([@B77]; [@B27]; [@B63]). However, mechanisms of P2X5R mediated effects in AT are unknown.

Taken together, there is good evidence that P2Rs affect a wide range of patho-/physiological processes in rodent and human AT. Many of these processes, e.g., lipid deposition, metabolism, endocrine activity, and inflammation, are deregulated during pathological states such as obesity and diabetes. However, P2Rs modulators have not yet been tested in clinical trials for treatment of metabolic disorders. Future research is still needed to dissect functions of P2R subtypes in adipocytes and AT before best P2R targets and drugs are selected.

Conclusion and Perspectives
===========================

In this review, we discussed contribution of P1 and P2 receptors to modulation of AT functions and considered processes that may underlie their role in metabolic disorders. Several preclinical studies indicate that pharmacological manipulation of purinergic signaling in adipocytes and AT has interesting potential for treating metabolic disorders. However, translation of these findings into clinical trials will require more detailed knowledge about the role of extracellular ATP and adenosine in the onset and progression of obesity-related disorders, as well as about the basic physiology and pharmacology of purinergic receptors expressed in adipocytes and in AT. In this context, it will be necessary to: (i) know differential expression of adenosine and P2Rs in white, brown and beige adipocytes belonging to different fat depots (subcutaneous, visceral, cardiac etc.); (ii) clarify sources and concentrations of nucleotides/sides and modifying enzymes present in specific AT microenvironments; (iii) understand role of purinergic system in interplay between different cells in AT microenvironment and potential patho-/physiological conditions which may affect those.
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